Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.

To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link

The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:
 Type of Tumor Marker
 ctDNA
 cfDNA
 CTCs
 Exosomes
 Others

 Application
 Diagnosis / Early Diagnosis
 Patient Monitoring
 Recurrence Monitoring

 Target Cancer Indication
 Breast Cancer
 Lung Cancer
 Colorectal Cancer
 Prostate Cancer
 Bladder Cancer
 Melanoma
 Gastric Cancer
 Pancreatic Cancer
 Ovarian Cancer
 Others

 End Users
 Hospitals
 Research Institutes
 Others

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Rest of the World

The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers report features the following companies, which we identified to be key players in this domain:
 Amoy Diagnostics
 DiaCarta
 HaploX Biotechnology
 NeoGenomics
 QIAGEN
 Swift Biosciences
 Sysmex Inostics
 Thermo Fisher Scientific
Press Release: Variation 3 (Format 4)

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Non-Invasive Cancer Screening and Diagnosis

5. Market Landscape

6. Company Profiles

7. Partnerships and Collaborations

8. Funding and Investment Analysis

9. Liquid Biopsy: Initiatives of Big Pharma Players

10. Key Acquisition Targets

11. Other Non-Invasive Cancer Diagnostics

12. Market Sizing and Opportunity Analysis

13. Survey Insights

14. Conclusion

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]